Sublin

Sublin is a French biotechnology company focused on developing a proprietary sublingual delivery platform for peptides and other large molecules. The company's technology aims to replace traditional injections with a non-invasive sublingual spray, improving patient quality of life and treatment adherence. Sublin's primary focus is the development of sublingual insulin for the treatment of diabetes mellitus. By leveraging the highly vascularized oral mucosa, the platform enables rapid systemic absorption while avoiding hepatic first-pass metabolism. The company is currently advancing its lead candidate through pre-clinical validation to demonstrate efficacy and safety compared to standard subcutaneous injections.